Premium
Difference in mesothelin‐binding ability of serum CA 125 between patients with endometriosis and epithelial ovarian cancer
Author(s) -
Sasaki Aya,
Akita Kaoru,
Ito Fumitake,
Mori Taisuke,
Kitawaki Jo,
Nakada Hiroshi
Publication year - 2014
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.29185
Subject(s) - mesothelin , endometriosis , ovarian cancer , medicine , cancer antigen , epithelial ovarian cancer , monoclonal antibody , oncology , antibody , cancer research , cancer , immunology
The epithelial ovarian carcinoma (EOC) is an aggressive malignant tumor, and is currently the leading cause of gynecologic cancer death. CA125 is the most commonly used serum marker for EOC, but shows a high‐false‐positive rate for several benign diseases such as endometriosis. The purpose of our study is therefore to identify a useful biochemical tool for detecting qualitative differences between CA125 from patients with endometriosis and EOC, and to facilitate differential diagnosis of these diseases. In our study, using two different CA125‐binding molecules, i.e ., recombinant mesothelin and an anti‐CA125 monoclonal antibody, a novel sandwich ELISA for determining the serum levels of CA125 with mesothelin‐binding ability (CA125 meso ) was developed, and tested for patients with endometriosis ( n = 59) and EOC ( n = 36). We found that both the serum CA125 meso level and the ratio of the serum CA125 meso to CA125 levels (CA125 meso /CA125) were significantly higher in patients with EOC than in patients with endometriosis ( p < 0.00005 and p < 0.1, respectively). Furthermore, receiver operating characteristic analysis showed that the CA125 meso assay was superior to the conventional antibody‐based CA125 assay in discriminating endometriosis from EOC. Thus, mesothelin‐binding ability may be a useful indicator for qualitatively evaluating CA125 in patients with endometriosis and EOC.